Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Knoll

Showing results (31-40 of 390) with videos related to

Pageof 39
Sort By:
Pharmacology & Toxicology|March 14, 1998
(-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brainJ Knoll
Acta Physiologica Academiae Scientiarum Hungaricae|January 1, 1981
Béla Issekutz 1886-1979J Knoll
Acta Neurologica Scandinavica. Supplementum|January 1, 1989
The pharmacology of selegiline ((-)deprenyl). New aspectsJ Knoll
Experimental Gerontology|July 1, 1997
Sexual performance and longevityJ Knoll
Journal of Neural Transmission. Supplementum|January 1, 1986
The pharmacology of (-)deprenylJ Knoll
Wiener Medizinische Wochenschrift. Supplement|January 1, 1986
[Medicamentous strategy for improving the quality of life in the senescence]J Knoll
Neurobiology (Budapest, Hungary)|November 4, 2000
(-)Deprenyl (Selegiline): past, present and futureJ Knoll
CNS Drug Reviews|October 19, 2001
Antiaging compounds: (-)deprenyl (selegeline) and (-)1-(benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective highly potent enhancer of the impulse propagation mediated release of catecholamine and serotonin in the brainJ Knoll
Polish Journal of Pharmacology and Pharmacy|March 1, 1978
Selective inhibition of noradrenergic transmission in vascular smooth muscleJ Knoll
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1995
Rationale for (-)deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changesJ Knoll
Pageof 39

Showing results (31-40 of 390) with videos related to

Sort By:
Pageof 39
Pharmacology & Toxicology|March 14, 1998
(-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brainJ Knoll
Acta Physiologica Academiae Scientiarum Hungaricae|January 1, 1981
Béla Issekutz 1886-1979J Knoll
Acta Neurologica Scandinavica. Supplementum|January 1, 1989
The pharmacology of selegiline ((-)deprenyl). New aspectsJ Knoll
Experimental Gerontology|July 1, 1997
Sexual performance and longevityJ Knoll
Journal of Neural Transmission. Supplementum|January 1, 1986
The pharmacology of (-)deprenylJ Knoll
Wiener Medizinische Wochenschrift. Supplement|January 1, 1986
[Medicamentous strategy for improving the quality of life in the senescence]J Knoll
Neurobiology (Budapest, Hungary)|November 4, 2000
(-)Deprenyl (Selegiline): past, present and futureJ Knoll
CNS Drug Reviews|October 19, 2001
Antiaging compounds: (-)deprenyl (selegeline) and (-)1-(benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective highly potent enhancer of the impulse propagation mediated release of catecholamine and serotonin in the brainJ Knoll
Polish Journal of Pharmacology and Pharmacy|March 1, 1978
Selective inhibition of noradrenergic transmission in vascular smooth muscleJ Knoll
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1995
Rationale for (-)deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changesJ Knoll
Pageof 39